DOP23: Myenteric plexitis and post-operative recurrence in Crohn’s disease: the role of enteric glial cells and ICAM-1
ECCO '19 Copenhagen
2019
DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis
ECCO '19 Copenhagen
2019
DOP27: Sequencing-based hematopoietic miRNA landscape reveals common and distinct features of autoimmune inflammatory phenotypesECCO '19 Copenhagen
2019
DOP28: Maternal obstetric outcomes in women with IBD compared with the general population
ECCO '19 Copenhagen
2019
DOP29: Pregnancy outcomes in IBD patients treated with vedolizumab, anti-TNF, or conventional therapy
ECCO '19 Copenhagen
2019
DOP30: Factors associated with life satisfaction in people with Crohn’s disease and ulcerative colitis: results from the national 2018 Crohn’s and Colitis UK Inflammatory Bowel Disease Quality of Life Survey
ECCO '19 Copenhagen
2019
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?
ECCO '19 Copenhagen
2019
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
ECCO '19 Copenhagen
2019
DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study
ECCO '19 Copenhagen
2019
DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study
ECCO '19 Copenhagen
2019
DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
ECCO '19 Copenhagen
2019
DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare
ECCO '19 Copenhagen
2019
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience
ECCO '19 Copenhagen
2019
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience
ECCO '19 Copenhagen
2019